| Prev Close | 203.97 |
| Day Low/High | 200.52 / 206.00 |
| 52 Wk Low/High | 200.47 / 276.69 |
Amgen Inc. (AMGN)
201.09
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 563.27B |
| Market Cap | 114.89B |
| P/E Ratio | 20.43 |
| Div & Yield | N.A. (N.A) |
Latest News
'Achieve' High Returns With These 3 Dividend Growth Stocks
These names are among our favorite Dividend Achievers, those companies with at least a decade of dividend growth.
Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip
While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.
3 Big Pharma Buys for Dividend Investors
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
Market on Eggshells, Masking Up, ISM, Pfizer and Moderna Just Getting Started
Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?
How Now, Dow Jones?
The Dow Jones Industrial Average is being dragged down by Amgen , Microsoft and Boeing .
My Beautiful Balloon, Unmasking the Market, Crypto Risk, Preparing for Powell
With the economy apparently growing robustly, the Fed has to watch how the president's plans play out in terms of the size and scope of deficit spending.
The Pullback Is on Schedule
Now, let's look at 2000, and see if we can spot any similarities....
Amgen Looks Ready for an Upside Breakout
Traders could go long at current levels risking below $240 for now.
Jim Cramer: Robbing Peter to Pay Paul
Let's review this Archegos drama and some lessons from this fickle market.
A Market No-Doubter, Vaccine Milestone, GDP Green Shoots, Inovio, Amazon, Google
The fact is that even if there is some compromise, the next fiscal stimulus package will be closer to $1.9 trillion than $600 billion.
Jim Cramer: Here's Why the Market Is Cheering Georgia's Results
The fears of what would happen from Democratic wins in Georgia's race failed to pan out, aside from tech taking a few hits. Here's what's happening instead and why.
Real Money Post Industrial Average Bests Most Major Indexes in 2020
As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.
My 10 'No Doubt' Predictions for 2021
From Amazon to Zoom, here are my prognostications and best ideas for the new year.
Let's See How These Dividend Gifts Stack Up
Let's compare several dividend increases in time for the holidays -- and see who wins the 'derby.'
Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week
These names are displaying technical deterioration.
A 3% Dividend Yield With Growth in the Pipeline
With four consecutive flat quarterly dividends, this pharmaceutical name could be on the verge of another hefty raise.
Real Money Post Industrial Average Rises 21% Year to Date
The average declined in October, but it was less than that hit took by the major indexes.
Surviving in This Environment, Shaky Recovery, Lilly and Pfizer Setbacks
The 'work from home' or 'economic lockdown' trade is close to being back on.
Eli Lilly Could Rally After Passing the Test
Successful tests of a rising 200-day moving average line can be great entry points for longs.
No Ordinary Month, Fear September?, Put/Call Ratio, TikTok Bidding War, Amazon
How September markets digest August ahead of momentous events will be far more important to uptrend maintenance than how August closed.
Pizza, Splits and Stocks
Apple's weight in the (price-weighted) Dow Jones Industrial Average, effective this morning, will be reduced from 12% to 3% -- based on the company's 4-1 stock split. In response to that split, Amgen , Honeywell , and Salesforce are being added to t...
Weakness in September? Dwindling Trading Volume, Fed Speak, Cybersecurity Stocks
September, not October, is historically the weakest month of the year for equity markets, though October has had more high profile collapses.
A Healthy Dose of Vaccine and Pharmaceutical Plays
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Amgen Might Be the Right Medicine for the Dow
Let's check the charts as this biotech replaces Pfizer on the DJIA.
Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
